Citadel Advisors’s Aligos Therapeutics ALGS Stock Holding History

Citadel Advisors’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-56	Closed	-$490	–	14160
2024 Q2	$490	Sell	56 -96	-63%	-$1.69K	﹤0.01%	13979
2024 Q1	$3.72K	Buy	+152	New	+$3.03K	﹤0.01%	13873
2023 Q3	–	Sell	-188	Closed	-$4.56K	–	14227
2023 Q2	$4.56K	Sell	188 -316	-63%	-$8.47K	﹤0.01%	13587
2023 Q1	$11K	Buy	504 +220	+77%	+$8.41K	﹤0.01%	13491
2022 Q4	$6.77K	Buy	+284	New	+$7.16K	﹤0.01%	13884
2022 Q1	–	Sell	-616	Closed	-$183K	–	13490
2021 Q4	$183K	Buy	+616	New	+$225K	﹤0.01%	11977

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's ALGS Position: Q2 2026 in Review

Citadel Advisors sold out of Aligos Therapeutics (ALGS) in Q2 2026, closing a stake of 54,311 shares — an estimated $404K sold.

Citadel Advisors first reported a position in ALGS in Q2 2021 and held it in 14 quarters. The position peaked at $483K in Q4 2025. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

Citadel Advisors reported no remaining Aligos Therapeutics position as of Q2 2026 after selling out during the quarter.
Citadel Advisors sold 54,311 Aligos Therapeutics shares in Q2 2026, an estimated $404K.
Citadel Advisors first reported a position in Aligos Therapeutics in Q2 2021 and held it in 14 quarters.
Citadel Advisors's Aligos Therapeutics position peaked at $483K in Q4 2025.
31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.